Harrow Health, Inc. 8.625% Senior Notes due 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 Fundamental Analysis
Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL) shows moderate financial fundamentals with a PE ratio of -246.50, profit margin of -1.89%, and ROE of -10.00%. The company generates $0.4B in annual revenue with strong year-over-year growth of 53.32%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 20.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HROWL's fundamental strength across five key dimensions:
Efficiency Score
WeakHROWL struggles to generate sufficient returns from assets.
Valuation Score
ModerateHROWL shows balanced valuation metrics.
Growth Score
ExcellentHROWL delivers strong and consistent growth momentum.
Financial Health Score
ModerateHROWL shows balanced financial health with some risks.
Profitability Score
WeakHROWL struggles to sustain strong margins.
Key Financial Metrics
Is HROWL Expensive or Cheap?
P/E Ratio
HROWL trades at -246.50 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, HROWL's PEG of 34.51 indicates potential overvaluation.
Price to Book
The market values Harrow Health, Inc. 8.625% Senior Notes due 2026 at 24.15 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 28.98 times EBITDA. This signals the market has high growth expectations.
How Well Does HROWL Make Money?
Net Profit Margin
For every $100 in sales, Harrow Health, Inc. 8.625% Senior Notes due 2026 keeps $-1.89 as profit after all expenses.
Operating Margin
Core operations generate 11.21 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-10.00 in profit for every $100 of shareholder equity.
ROA
Harrow Health, Inc. 8.625% Senior Notes due 2026 generates $-1.29 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Harrow Health, Inc. 8.625% Senior Notes due 2026 produces operating cash flow of $63.67M, showing steady but balanced cash generation.
Free Cash Flow
Harrow Health, Inc. 8.625% Senior Notes due 2026 generates strong free cash flow of $62.32M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.17 in free cash annually.
FCF Yield
HROWL converts 3.37% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-246.50
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
34.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
24.15
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
4.80
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.20
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.10
vs 25 benchmark
ROA
Return on assets percentage
-0.01
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How HROWL Stacks Against Its Sector Peers
| Metric | HROWL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -246.50 | 28.25 | Better (Cheaper) |
| ROE | -10.00% | 780.00% | Weak |
| Net Margin | -1.89% | -20122.00% (disorted) | Weak |
| Debt/Equity | 4.80 | 0.30 | Weak (High Leverage) |
| Current Ratio | 2.20 | 4.66 | Strong Liquidity |
| ROA | -1.29% | -14687.00% (disorted) | Weak |
HROWL outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Harrow Health, Inc. 8.625% Senior Notes due 2026's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
177.12%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-7490.95%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-1760.01%
Industry Style: Defensive, Growth, Innovation
Declining